Development of a Beta Cell-Specific Expression Control Element for Recombinant Adeno-Associated Virus

Area of Science:

• Gene therapy
• Molecular biology
• Endocrinology

Background:

• Diabetes mellitus results from beta cell loss or dysfunction.
• Recombinant adeno-associated virus (rAAV)-mediated gene therapy is a promising approach for diabetes.
• Targeting therapeutic payloads specifically to beta cells requires cell type-specific expression control.

Purpose of the Study:

• To develop and test rAAV vectors for specific transgene expression in human beta cells.
• To identify effective regulatory elements for beta cell-specific gene expression.
• To reduce off-target gene expression in non-beta cells.

Main Methods:

• Testing various rAAV vectors with different insulin promoter fragments.
• Evaluating promoter activity and specificity in human beta cells and other cell types.
• Utilizing microRNA recognition elements (MREs) for negative regulation in alpha cells.

Main Results:

• A small insulin promoter fragment (84 bp) and a larger fragment (363 bp) lacked beta cell specificity.
• Combining two copies of the insulin promoter (INS×2) with MREs achieved high beta cell specificity.
• The INS×2-MRE vector effectively reduced transgene expression in alpha cells.

Conclusions:

• The INS×2-MRE expression vector demonstrates high specificity for human beta cells and stem cell-derived beta cells.
• This vector is a valuable tool for rAAV-mediated gene therapy targeting beta cells in diabetes.
• The combination of a duplicated promoter and miRNA-mediated regulation offers precise cell-specific gene expression.